Enovis Corp Dossier
Qualitative Analysis
Business overview
Enovis Corporation (NYSE: ENOV), formerly known as Colfax Corporation, is an innovation-driven medical technology growth company headquartered in Wilmington, Delaware. The company operates through two primary segments: Reconstructive (Recon) and Prevention & Recovery (P&R). The Reconstructive segment develops, manufactures, and distributes surgical implants, instrumentation, and enabling technologies (such as the ARVIS surgical navigation system) used in joint replacement, limb reconstruction, and extremities procedures. The Prevention & Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, and vascular therapy systems under well-known brands like DonJoy. Enovis serves a global customer base, including orthopedic specialists, surgeons, physical therapists, and athletic trainers, capitalizing on secular demographic trends such as an aging population and active lifestyles.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Scaling the ARVIS augmented reality surgical visualization and intraoperative guidance system, with planned new launches in knee and shoulder arthroplasty.
Expected impact: Differentiates the Reconstructive portfolio, drives surgeon adoption, and expands presence in the high-growth Ambulatory Surgery Center (ASC) market.
Executing the multi-year integration playbook for LimaCorporate S.p.A. to consolidate operations, leverage 3D-printing capabilities, and capture cost synergies.
Expected impact: Targeting $40 million in cost synergies and supporting the expansion of adjusted EBITDA margins toward 18-20%.
Launching and scaling the first-of-its-kind hybrid scoliosis brace combining rigid corrective performance with dynamic wearability.
Expected impact: Improves patient compliance in adolescent idiopathic scoliosis and expands the Prevention & Recovery segment's market share.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To position Enovis as a global leader in reconstructive surgery, expand its international reach (especially in Europe), and acquire advanced 3D-printed implant technology.
Financial impact: Significantly expanded the Reconstructive segment, helping push total reconstructive sales past the $1 billion milestone.
To strengthen Enovis' foot and ankle portfolio and accelerate growth in the minimally invasive surgery (MIS) solutions market.
Financial impact: Broadened reconstructive product offerings and expanded the customer base in Europe.
Strategic Partnerships
Expands Enovis' product offerings and distribution networks by distributing bone matrix allografts.